Diminished Global Arginine Bioavailability and Increased Arginine Catabolism as Metabolic Profile of Increased Cardiovascular Risk  by Tang, W.H. Wilson et al.
N
e
l
n
s
N
m
F
B
C
O
H
H
W
S
c
t
L
Journal of the American College of Cardiology Vol. 53, No. 22, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
PCardiovascular Risk
Diminished Global Arginine Bioavailability
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Metabolic Profile of Increased Cardiovascular Risk
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Stanley L. Hazen, MD, PHD*†
Cleveland, Ohio
Objectives We hypothesized that an integrated assessment of arginine with its catabolic products might better predict car-
diovascular risks than arginine levels alone.
Background Arginine is the sole nitrogen source for nitric oxide (NO) synthesis. The major catabolic products of arginine are
ornithine and citrulline.
Methods Plasma levels of free arginine, ornithine, citrulline, and the endogenous NO synthase inhibitor asymmetric dim-
ethylarginine (ADMA) were measured with liquid chromatography coupled with tandem mass spectrometry. We
examined the relationship of global arginine bioavailability ratio (GABR) (defined as arginine/[ornithine  citrul-
line]) versus arginine and its catabolic metabolites to prevalence of significantly obstructive coronary artery dis-
ease (CAD) and incidence of major adverse cardiovascular events (MACE) (death, myocardial infarction, stroke)
over a 3-year follow-up in 1,010 subjects undergoing elective cardiac catheterization.
Results Patients with significantly obstructive CAD had significantly lower GABR (median [interquartile range]: 1.06 [0.75
to 1.31] vs. 1.27 [0.96 to 1.73], p  0.001) and arginine levels [mean: 68  20 mol/l vs. 74  24 mol/l,
p  0.001) than those without significantly obstructive CAD. After adjusting for Framingham risk score,
C-reactive protein, and renal function, lower GABR (but not arginine levels) and higher citrulline levels remained
significantly associated with both the prevalence of significantly obstructive CAD (adjusted odds ratio: 3.93,
p  0.001, and 5.98, p  0.001, respectively) and 3-year risk for the incidence of MACE (adjusted hazard ratio:
1.98, p  0.025, and 2.40, p  0.01, respectively) and remained significant after adjusting for ADMA.
Conclusions GABR might serve as a more comprehensive concept of reduced NO synthetic capacity compared with systemic
arginine levels. Diminished GABR and high citrulline levels are associated with both development of significantly
obstructive atherosclerotic CAD and heightened long-term risk for MACE. (J Am Coll Cardiol 2009;53:2061–7)
© 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.036b
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Aitric oxide (nitrogen monoxide) (NO) is an important
ndothelium-derived vasoactive substance critical to vascu-
ar health and homeostasis (1). Arginine serves as the sole
itrogen source for NO synthases. Nitric oxide is synthe-
ized from arginine in a multistep reaction carried out by
O synthases, producing NO and citrulline (Fig. 1). Nu-
erous lines of evidence indicate that diminished NO
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Arginine Catabolism and Cardiovascular Risk June 2, 2009:2061–7proves NO production in the coro-
nary arteries (2–6), although results
of oral arginine supplementation
studies have been variable (7–9).
Therefore, assessing arginine bio-
availability might provide an im-
portant insight into cardiovascular
health not achievable by directly
assessing arginine levels (10) and
might potentially identify pa-
tients who might receive the great-
est benefit from enhancing argi-
nine bioavailability.
Arginine is the common sub-
strate for both NO synthases and
arginases (Fig. 1) (11). In several
isease states, arginase levels are increased and have been
roposed to limit NO formation through increased arginine
onsumption. This limiting of NO formation results in
ndirect competition with NO synthases and the formation
f ornithine and subsequently citrulline (12,13). In turn,
itrulline (also a direct product of NO synthases) might
onvert back to arginine via the formation of argininosuc-
inate (primarily in the kidneys) (14). Hence, we hypothe-
ized that the “bioavailability” of arginine might be im-
acted by different processes that might reduce arginine
vailability to NO synthases. We therefore proposed a
oncept of “global arginine bioavailability ratio” (GABR) to
ccount for levels of the substrate (arginine) and its major
atabolic products (ornithine and citrulline) in vivo. Specif-
cally, we tested the hypothesis that plasma levels of GABR
Figure 1 Schematic Illustration of Pathways for NO Production
ADMA  asymmetric dimethylarginine; L-NMMA  NG-mono-methyl-L-arginine; NO 
Abbreviations
and Acronyms
ADMA  asymmetric
dimethylarginine
CAD  coronary artery
disease
GABR  global arginine
bioavailability ratio
hsCRP  high-sensitivity
C-reactive protein
MACE  major adverse
cardiovascular event(s)
MI  myocardial infarction
NO  nitric oxideould be more highly predictive of the development and
rogression of cardiovascular diseases than plasma levels of
ree arginine. We verified this prediction by measuring the
revalence of significantly obstructive coronary artery dis-
ase (CAD) at baseline and the subsequent incidence of
ajor adverse cardiovascular events (MACE) in our study
opulation. We further explored the relative prognostic
alue of GABR with asymmetric dimethylarginine (ADMA),
n endogenous direct NO synthase inhibitor.
ethods
tudy population. The Cleveland Clinic GeneBank study
s a large, single-center, prospective, cohort study with
lasma, serum, and deoxyribonucleic acid repository ob-
ained from sequential subjects undergoing elective diagnos-
ic cardiac catheterization. The Cleveland Clinic Institu-
ional Review Board approved the study, and all participants
ave written informed consent. Clinical and demographic
nformation was collected at the time of enrollment, and
ata were de-identified before analysis. This study used
lasma samples obtained from 1,010 consecutive subjects
nrolled in GeneBank. The Framingham Risk score (in-
luding diabetes) was calculated for each subject, and the
lomerular filtration rate was estimated by the Modification
f Diet in Renal Disease (MDRD) formula. High-
ensitivity C-reactive protein (hsCRP), creatinine, fasting
lood glucose, and lipid profiles were measured on the
bbott ARCHITECT platform (Abbott Laboratories,
nc., Abbott Park, Illinois). Over the 3 years after enrollment,
djudicated outcomes were ascertained for all subjects.
Arginine Catabolism
oxide; NOS  nitric oxide synthases.and
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June 2, 2009:2061–7 Arginine Catabolism and Cardiovascular Riskata extraction and end points. Significantly obstructive
AD was defined as any clinical history of myocardial
nfarction (MI), percutaneous coronary intervention, coro-
ary artery bypass surgery, acute coronary syndrome, or
ngiographic evidence of CAD (50% stenosis) in 1 or
ore major coronary arteries. A MACE was defined as the
ccurrence of nonfatal MI, nonfatal stoke, or death within
years of follow-up. All clinical outcomes were adjudicated
ith source documentation.
ample collection and measurements. Samples were col-
ected from fasting subjects on the day of elective cardiac
atheterization. Plasma aliquots analyzed were isolated from
hole blood collected in ethylene-diamine-tetra-acetic acid
lavender top) tubes, which were maintained at 0°C to 4°C
mmediately after phlebotomy, processed within 4 h of blood
raw, and stored at 80°C until use. Plasma arginine, orni-
hine, citrulline, and ADMA levels were determined by stable
sotope dilution high-performance liquid chromatography with
nline electrospray ionization tandem mass spectrometry (LC/
SI/MS/MS) with an API 365 triple quadruple mass spec-
rometer (Applied Biosystems, Foster City, California) with an
onics 10 redesigned source as an upgrade, and interfaced
ith a Cohesive high-performance liquid chromatography
Franklin, Massachusetts). 13C6-arginine was used as the
nternal standard and added at the time of plasma aliquot
hawing. Plasma proteins were precipitated with 80% metha-
ol and supernatant, after centrifugation at 5,000 g for 10 min,
°C, and were collected for determination of the analyte
oncentration as described (15).
tatistical analysis. The Wilcoxon rank-sum test for con-
inuous variables and chi-square test for categorical variables
ere used to examine the difference between the groups.
Baseline Characteristics of Study Population
Table 1 Baseline Characteristics of Study P
N
O
Demographics and cardiovascular risk factors
Age (yrs)
Female
Diabetes
Hypertension
Framingham risk score
Current smokers
Laboratory data
LDL cholesterol
HDL cholesterol
Triglycerides 1
hsCRP (mg/dl)
Creatinine clearance
Arginine (mol/l)
Ornithine (mol/l) 3
Citrulline (mol/l) 1
GABR 1
Values are mean  SD, %, or median (interquartile range).
CAD  coronary artery disease; GABR  global arginine bioavailability ratio
protein; IQR  interquartile range; LDL  low-density lipoprotein.he GABR was divided into quartiles for analysis. Unad-
usted trends for increasing significantly obstructive CAD
nd MACE at 3 years with increasing or decreasing
uartiles were evaluated with the log-rank test of trend.
ecause diminished GABR (i.e., lower values) portend
reater risk, logistic regression models were developed to
alculate odds ratios (ORs) or hazard ratios (HRs) associ-
ted with the first, second, and third quartiles of GABR,
hich were compared with the highest quartile. Adjust-
ents were made for Framingham Global Risk Score,
reatinine clearance, and plasma hsCRP levels. Kaplan-
eier analysis with Cox proportional hazards regression
as used for time-to-event analysis. A Spearman correlation
oefficient was calculated to summarize the correlation
etween GABR and ADMA. All analyses were performed
ith SAS version 8.2 (SAS Institute, Cary, North Caro-
ina). Values of p  0.05 were considered statistically
ignificant.
esults
tudy population. Table 1 illustrates the clinical charac-
eristics of the study population, stratified according to the
resence or absence of significantly obstructive CAD. As
xpected, patients with significantly obstructive CAD were
ore likely to be older and have 1 or more cardiovascular
isk factors (diabetes mellitus and hypertension). In our
nalysis, plasma arginine level was normally distributed,
hereas ornithine, citrulline, and GABR were not.
lasma levels of arginine, GABR, and significantly ob-
tructive CAD. Compared with those without signifi-
antly obstructive CAD, patients with significantly obstruc-
ive CAD had significantly lower levels of plasma arginine
tion
ificantly
tive CAD
402)
Significantly
Obstructive CAD
(n  608) p Value
 8 66 10 0.001
3 52 0.772
5 45 0.001
4 78 0.001
 3.4 8.5 4.0 0.001
5 6 0.318
 33 100 35 0.001
 17 44 14 0.001
–168) 141 (105–212) 0.001
1–4.6) 3.3 (1.7–7.6) 0.001
 32.8 88.2 40.0 0.001
 24 68 20 0.001
.9–49.1) 41.3 (29.9–56.6) 0.001
.7–26.0) 23.4 (17.5–31.0) 0.001
96–1.73) 1.06 (0.75–1.31) 0.001opula
o Sign
bstruc
(n 
61
5
1
5
6.6
108
53
17 (83
2.2 (1.
99.2
74
5.9 (25
7.7 (13
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Arginine Catabolism and Cardiovascular Risk June 2, 2009:2061–7ut higher levels of ornithine and citrulline (Table 1). This
irectly leads to significantly lower median GABR in
atients with significantly obstructive CAD versus those
ithout (median [interquartile range]: 1.06 [0.75 to 1.31]
s. 1.27 [0.96 to 1.73], p  0.001). After adjustment for
raditional risk factors, creatinine clearance, and hsCRP,
ABR levels remained significantly associated with preva-
ent significantly obstructive CAD (quartile 1 compared
ith quartile 4; adjusted OR: 3.93 [95% confidence interval
CI): 2.55 to 6.05], p  0.001) (Table 2). Higher ornithine
nd citrulline levels were also associated with a higher
revalence of significantly obstructive CAD (Table 3). In
ontrast, whereas lower plasma arginine levels were associ-
ted with higher significantly obstructive CAD prevalence
cross quartiles in unadjusted analysis, low plasma arginine
evels were no longer a predictor of prevalence of signifi-
nadjusted and Adjusted Risk for Significantly Obstructive CADrevalence MACE at 3 Years With Decreasing Q artiles of GAB
Table 2 Unadjusted and Adjusted Risk for Significantly ObstrucPrevalence and MACE at 3 Years With Decreasing Qua
4th Quartile
GABR 1.46
Significantly obstructive CAD prevalence
Unadjusted OR (95% CI) 1.0
Adjusted OR (95% CI) 1.0
MACE at 3 yrs
Unadjusted HR (95% CI) 1.0
Adjusted HR (95% CI) 1.0
Arginine (mol/l) 82.8
Significantly obstructive CAD prevalence
Unadjusted OR (95% CI) 1.0
Adjusted OR (95% CI) 1.0
MACE at 3 yrs
Unadjusted HR (95% CI) 1.0
Adjusted HR (95% CI) 1.0
p  0.001; †p  0.01; ‡p  0.05.
CAD  coronary artery disease; CI  confidence interval; GABR  global arginine bioavailabilit
nadjusted and Adjusted Risk for Significantly Obstructive CADrevalence MACE at 3 Years With Increasing Quar l s of Citru
Table 3 Unadjusted and Adjusted Risk for Significantly ObstrucPrevalence and MACE at 3 Years With Increasing Qua
1st Quartile
Citrulline (mol/l) 15.3
Significantly obstructive CAD prevalence
Unadjusted OR (95% CI) 1.0
Adjusted OR (95% CI) 1.0
MACE at 3 yrs
Unadjusted HR (95% CI) 1.0
Adjusted HR (95% CI) 1.0
Ornithine (mol/l) 28.3
Significantly obstructive CAD prevalence
Unadjusted OR (95% CI) 1.0
Adjusted OR (95% CI) 1.0
MACE at 3 yrs
Unadjusted HR (95% CI) 1.0
Adjusted HR (95% CI) 1.0p  0.05; †p  0.001; ‡p  0.01.
Abbreviations as in Table 2.antly obstructive CAD after adjusting for traditional risk
actors, creatinine clearance, and hsCRP (adjusted OR: 1.19
95% CI: 0.79 to 1.80], p  0.40) (Table 2).
lasma arginine metabolite levels, GABR, and MACE.
mong the 991 subjects with 3-year follow-up, there were
26 (12.7%) incident MACE events. Analytes were again
ivided into quartiles for analyses of risk prediction, and the
ates of nonfatal MI or stroke, all-cause mortality, as well as
he composite MACE examined (Fig. 2). Overall, GABR
cross decreasing quartiles provided a consistent incremen-
al association with increasing incident MACE. Figures 3 and 4
how the Kaplan-Meier time-to-event curves for the occur-
ence of MACE for each quartile of GABR and citrulline,
espectively. After adjustment for Framingham risk score,
sCRP, and creatinine clearance, subjects with lowest ab-
olute values of GABR and highest levels of citrulline
d Arginine Levels
CAD
of GABR and Arginine Levels
rd Quartile 2nd Quartile 1st Quartile
1.14–1.46 0.82–1.14 0.82
(1.68–3.47)* 3.28 (2.26–4.75)* 3.63 (2.50–5.28)*
(1.86–4.09)* 3.77 (2.49–5.72)* 3.93 (2.55–6.05)*
(0.89–3.12) 2.27 (1.25–4.11)† 3.64 (2.08–6.39)*
(0.75–2.67) 1.42 (0.77–2.63) 1.98 (1.09–3.59)‡
68.5–82.8 55.3–68.4 55.3
(1.18–2.42)† 1.74 (1.21–2.49)† 1.94 (1.35–2.79)*
(1.12–2.56)‡ 1.23 (0.82–1.85) 1.19 (0.79–1.80)
(0.75–2.32) 1.55 (0.90–2.66) 1.85 (1.10–3.14)‡
(0.65–2.10) 1.15 (0.66–2.01) 1.22 (0.70–2.12)
HR  hazard ratio; MACE  major adverse cardiac event(s); OR  odds ratio.
and Ornithine Levels
CAD
of Citrulline and Ornithine Levels
nd Quartile 3rd Quartile 4th Quartile
5.3–21.2 21.3–29.4 29.4
(1.05–2.15)* 2.91 (2.01–4.20)† 3.17 (2.18–4.61)†
(1.14–2.46)‡ 3.63 (2.40–5.51)† 5.98 (3.72–9.60)†
(0.87–2.97) 2.21 (1.2–3.96)‡ 3.35 (1.93–5.82)†
(0.87–3.01) 1.89 (1.05–3.1)* 2.40 (1.34–4.30)‡
8.3–38.9 38.9–53.7 53.8
(0.91–1.85) 1.67 (1.17–2.39)‡ 2.29 (1.58–3.32)†
(0.92–1.99) 2.32 (1.54–3.49)† 3.95 (2.53–6.18)†
(0.66–1.89) 1.44 (0.86–2.40) 1.54 (0.93–2.54)
(0.62–1.83) 1.16 (0.68–1.98) 1.23 (0.73–2.06)R an
tive
rtiles
3
2.41
2.76
1.67
1.41
1.69
1.69
1.32
1.17lline
tive
rtiles
2
1
1.50
1.67
1.61
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June 2, 2009:2061–7 Arginine Catabolism and Cardiovascular Riskhowed the greatest risk for incident MACE over the 3
ears after angiography. In contrast, arginine and ornithine
uartiles did not predict incident MACE risk at 3 years
Tables 2 and 3).
Additional analyses were performed, looking at the rela-
ionship between GABR and ADMA in predicting preva-
ence of significantly obstructive CAD and incidence of
ACE (3 years) within the cohort. Overall, GABR and
DMA showed a modest negative correlation (r  0.24,
 0.001). After adjusting for ADMA, the lowest quartile
f GABR remained independently predictive of both a
igher prevalence of significantly obstructive CAD (ad-
usted OR: 3.28 [95% CI: 2.24 to 4.82], p  0.001) and a
igher incidence of MACE (adjusted HR: 2.93 [95% CI:
.66 to 5.20], p  0.001) when compared with the highest
uartile of GABR. Similar observations were made in the
ighest quartile of citrulline after adjusting for ADMA for
igher incidence of MACE (adjusted HR: 2.03 [95% CI:
Figure 2
Distribution of MI/Stroke, All-Cause
Mortality, and 3-Year Incidence of MACE
According to GABR and Arginine Quartiles
p value for trend. GABR  global arginine bioavailability ratio;
MACE  major adverse cardiovascular event(s); MI  myocardial infarction..44 to 2.87], p  0.001).iscussion
he relationships among plasma arginine levels, NO biosyn-
hesis, and cardiovascular disease are complex. Arginine par-
icipates in various metabolic reactions that differ by compart-
ents and are modulated by diet, cytokines, and hormones
14). To our knowledge, our study is the largest experience to
ate to address the clinical significance of assessing systemic
evels of arginine metabolites for cardiovascular risks in hu-
ans. Our study demonstrates the importance of assessing
atabolites of arginine metabolism and shows the ability to
Figure 3
Kaplan-Meier Survival Analysis
for Patients With 3-Year Incidence
of MACE According to GABR Quartiles
GABR  global arginine bioavailability ratio;
MACE  major adverse cardiovascular event(s).
Figure 4
Kaplan-Meier Survival Analysis
for Patients With 3-Year Incidence
of MACE According to Citrulline Quartiles
MACE  major adverse cardiovascular event(s).
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Arginine Catabolism and Cardiovascular Risk June 2, 2009:2061–7redict cardiovascular disease prevalence and future risks for
ACE when accounting for catabolic products of arginine
ornithine and citrulline). These findings were independent of
raditional cardiovascular risk factors, renal function, and
arkers of inflammation, even when accounting for levels of
he endogenous NO synthase inhibitor ADMA.
Increasing arginine as substrate for NO synthases has
een postulated to increase endothelial NO production (1).
owever, arginine supplementation studies have demon-
trated mixed outcomes with respect to cardiovascular dis-
ase outcomes (7). The underlying mechanisms for this are
ot clear. Under physiologic conditions, the intracellular
O synthases should be adequately saturated with their
rginine substrates. Enhanced NO production observed in
esponse to elevations in extracellular arginine, despite high
ntracellular arginine concentrations, is often referred to as
he “arginine paradox” (16,17). Several investigators have
ostulated that endogenous inhibitors of NO synthases,
ethylated arginine metabolites such as ADMA, might
rovide the explanation (16). Indeed, our group and others
ave demonstrated the clinical significance of elevated
lasma ADMA levels in cardiovascular risks (15,18–20). In
articular, data have suggested that a reduction in intracel-
ular concentrations of competitive and noncompetitive
nhibitors by extracellular arginine displacement might aug-
ent NO synthase activity, thereby increasing NO produc-
ion (21).
Our current data provide an alternative (or complemen-
ary) explanation for the arginine paradox, whereby a
elative deficiency of arginine for NO synthases caused by
ugmented “catabolic pathways” of arginine (such as argin-
ses) can in part contribute to underlying CAD and devel-
pment of cardiovascular events. Whereas in vitro studies
ave indicated an association between decreases in arginine
oncentrations—both systemic and locally—within athero-
clerotic plaques as well as impairment of the endothelial
O synthase-mediated stress responses (22), systemic argi-
ine levels have not been correlated with the prevalence of
AD (10). Also, arginine supplementation studies have
hus far failed to demonstrate improvement in cardiovascu-
ar outcomes (8). Several studies have suggested that a
elative arginine deficiency exists in subjects with hyperten-
ion or heart failure as a result of abnormal transport
echanisms across vascular cellular membranes (13,23,24).
xtracellular concentrations of arginine can also depend on
atabolism of the amino acid via several pathways, including
ugmented degradation of arginine, which might lead to
elative NO deficiency and subsequent progression of car-
iovascular disease.
Arginases, in particular, have been shown to be up-
egulated in several disease states with components of
nflammation including CAD, cystic fibrosis, sickle cell
isease, and asthma (25). Indeed, arginases are subject to
egulation by inflammatory cytokines as well as inter-
egulation by the arginine metabolites themselves (26).
ncreased arginase activity in endothelial cells has been rrgued to promote a pro-atherogenic effect, because of
irect reduction of endothelial cell NO production via the
onversion of arginine to ornithine (2). Indeed, it has been
uggested that indirect strategies for elevating arginine (such
s the inhibition of arginase) could prove more effective at
mproving intracellular arginine bioavailability than exoge-
ous arginine administration (2). Further support for this
pproach might be seen in smooth muscle cells, where
eightened arginine catabolic processes could result in
ncreased production of collagen and enhanced cell prolif-
ration attributable to the metabolism of ornithine into
roline and polyamines, respectively. The recently demon-
trated association between the arginase I gene polymor-
hism, rs2781666, and both heightened MI risk and in-
reased carotid intimal medial thickness is consistent with
he hypothesis that arginine catabolic processes are linked to
AD pathogenesis (27). Meanwhile, the downstream ef-
ects of diminished arginine bioavailability leading to pro-
ression of cardiovascular disease have also been investi-
ated. One suggestion has been the impact of this decreased
vailability of arginine on the synthesis of NO by interfering
ith NO synthase messenger ribonucleic acid translation via
ltered phosphorylation and activity of eukaryotic initiation
actor (28).
tudy limitations. Only plasma samples at a single time
oint were analyzed, and there were no direct physiologic
ascular measures to directly link vascular functional
hanges with diminished GABR and cardiovascular risks.
owever, numerous studies have demonstrated enhanced
ascular NO responses after arginine administration (3,5,7),
onditions that correspondingly will increase GABR. It is
lso conceivable that underlying metabolic processes not
onsidered and other medical therapies might have the
otential to alter the plasma sample measurements. We also
cknowledge that the proposed ratio of substrates and
roducts of arginine metabolism as defined by GABR fails
o take into account important issues such as compartmen-
ation and the fact that biological systems represent dynamic
ystems striving toward achieving steady-state conditions,
ot equilibria. Finally, measuring the levels of arginine and
ts related metabolites poses challenges due to the influence
f food intake and analytical constraints on amino acid
evels. Nevertheless, it should be emphasized that our study
sed fasting samples and quantitatively robust stable isotope
ilution mass spectrometry techniques. The relatively large
ample size further helps overcome these potential limita-
ions. Nevertheless, further studies should be conducted to
etermine the prognostic value of GABR or citrulline levels
lone in a prospective fashion under a broader range of
onditions to determine its prognostic value as a biomarker
nd its potential to guide metabolic therapy. Better under-
tanding of the mechanistic underpinnings of metabolic and
ascular abnormalities might provide the basis for further
nvestigations to explore the impact of a variety of treatment
trategies aiming to improve arginine bioavailability and
educe cardiovascular risks.
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June 2, 2009:2061–7 Arginine Catabolism and Cardiovascular Riskonclusions
he GABR, a novel comprehensive concept of arginine
etabolism that accounts for arginine catabolic metabolites,
ight provide a better index of reduced NO synthetic
apacity than systemic arginine levels alone. In our study
opulation of stable patients undergoing elective coronary
ngiography, lower GABR and higher citrulline levels were
ssociated with both a higher prevalence of significantly
bstructive atherosclerotic CAD and a higher risk of inci-
ent MACE during the first 3 years after angiography.
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